J Biol Regul Homeost Agents. 2011 Jan-Mar;25(1):1-6.
Sublingual immunotherapy (SLIT) is now recognized as a viable alternative to the classical injection route and it is currently used in everyday clinical practice in Europe. Sublingual administration is particularly attractive for children since it is completely pain-free. To date, no fatalities from SLIT have been reported, but two cases of anaphylaxis to inhalant allergens have been reported. The large majority of the adverse events reported in literature is described as mild. Most of them involve the mouth (burning or itching) or the gastrointestinal tract (stomachache, nausea) and usually self-resolve in a few days without any intervention. At present, SLIT represents the main option for allergists, however, tablet immunotherapy could become an interesting alternative to sublingual drops.
舌下免疫疗法（SLIT）现在被认为是经典注射途径的可行替代方案，目前在欧洲的日常临床实践中使用。舌下给药特别吸引儿童，因为它完全无痛。迄今为止，尚无 SLIT 导致死亡的报道，但有两起因吸入性过敏原引起过敏反应的报告。文献中报告的大多数不良事件被描述为轻度。其中大多数涉及口腔（烧灼感或瘙痒）或胃肠道（胃痛、恶心），通常在几天内自行缓解，无需任何干预。目前，SLIT 是过敏症专家的主要选择，然而，片剂免疫疗法可能成为舌下滴剂的一个有趣替代方案。
